Get notified when ELTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes a going concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operations.
Elicio Therapeutics prices $15M offering of 4.38M shares at $3.91; new investors face $2.90/share dilution
Filed July 2, 2026 · ~1 min read
Key Changes
-
high
Elicio is selling 4,380,313 shares at $3.91 per share, raising $15.0 million gross; net proceeds to the company are about $13.6 million.
The Offering verify on EDGAR → -
high
New investors will experience immediate dilution of $2.90 per share, the difference between the offering price and the as-adjusted net tangible book value of $0.53 per share.
Dilution verify on EDGAR → -
high
Net proceeds will primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic pancreatic cancer, plus pipeline and working capital.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade ELTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify